Matches in SemOpenAlex for { <https://semopenalex.org/work/W4320165055> ?p ?o ?g. }
Showing items 1 to 90 of
90
with 100 items per page.
- W4320165055 endingPage "44" @default.
- W4320165055 startingPage "37" @default.
- W4320165055 abstract "Asthma is one of the most common chronic diseases, with ≤25% of patients experiencing uncontrolled disease.1Patients with uncontrolled, moderate-to-severe asthma are at increased risk of recurrent exacerbations, accelerated decline in lung function, fixed airway obstruction, and have increased utilisation of health care resources.2,3Furthermore, reduced lung function, as assessed by measures such as forced expiratory volume in 1 second (FEV1), is a strong independent predictor of exacerbations, progressive decline in lung function, and all-cause pulmonary and cardiovascular mortality in patients with asthma.2 Achieving asthma control in these patients is therefore critical. The recognition of distinct inflammatory phenotypes within this population has been instrumental in addressing this need. In these patients, there is robust evidence of the pathogenic role of Th2 cytokines, such as IL-4 and IL-13, in the eosinophilic and allergic inflammatory processes.4This in turn has driven the development of targeted biological therapies, particularly selective targeted monoclonal antibodies such as dupilumab which inhibit the biological effects of both IL-4 and IL-13.5 This article reviews four posters displayed at the European Respiratory Society (ERS) International Congress 2019 that presented results demonstrating the efficacy and safety of dupilumab, an anti-IL-4 receptor human monoclonal antibody, compared to placebo for the treatment of uncontrolled, moderate-to-severe asthma, as measured by a range of outcomes." @default.
- W4320165055 created "2023-02-13" @default.
- W4320165055 creator A5011439031 @default.
- W4320165055 date "2019-12-12" @default.
- W4320165055 modified "2023-09-27" @default.
- W4320165055 title "Integrating Selective Targeted Monoclonal Antibody Therapies for Improved Outcomes in Uncontrolled Asthma" @default.
- W4320165055 cites W1886340528 @default.
- W4320165055 cites W2058856567 @default.
- W4320165055 cites W2064243251 @default.
- W4320165055 cites W2065452554 @default.
- W4320165055 cites W2076283455 @default.
- W4320165055 cites W2101401558 @default.
- W4320165055 cites W2105521580 @default.
- W4320165055 cites W2114703024 @default.
- W4320165055 cites W2149767222 @default.
- W4320165055 cites W2150009399 @default.
- W4320165055 cites W2161325421 @default.
- W4320165055 cites W2524051065 @default.
- W4320165055 cites W2594033175 @default.
- W4320165055 cites W2756181502 @default.
- W4320165055 cites W2801759342 @default.
- W4320165055 cites W2803941918 @default.
- W4320165055 cites W2805002966 @default.
- W4320165055 cites W2989651941 @default.
- W4320165055 cites W2990010694 @default.
- W4320165055 cites W2990927666 @default.
- W4320165055 cites W2991486578 @default.
- W4320165055 cites W3014613400 @default.
- W4320165055 cites W4236799899 @default.
- W4320165055 cites W4241647069 @default.
- W4320165055 cites W4246246555 @default.
- W4320165055 cites W4250325147 @default.
- W4320165055 cites W642101920 @default.
- W4320165055 doi "https://doi.org/10.33590/emj/10314575" @default.
- W4320165055 hasPublicationYear "2019" @default.
- W4320165055 type Work @default.
- W4320165055 citedByCount "0" @default.
- W4320165055 crossrefType "journal-article" @default.
- W4320165055 hasAuthorship W4320165055A5011439031 @default.
- W4320165055 hasBestOaLocation W43201650551 @default.
- W4320165055 hasConcept C126322002 @default.
- W4320165055 hasConcept C142724271 @default.
- W4320165055 hasConcept C159654299 @default.
- W4320165055 hasConcept C177713679 @default.
- W4320165055 hasConcept C203014093 @default.
- W4320165055 hasConcept C204787440 @default.
- W4320165055 hasConcept C27081682 @default.
- W4320165055 hasConcept C2776042228 @default.
- W4320165055 hasConcept C2777037409 @default.
- W4320165055 hasConcept C2777832160 @default.
- W4320165055 hasConcept C2779185760 @default.
- W4320165055 hasConcept C2779824493 @default.
- W4320165055 hasConcept C2908647359 @default.
- W4320165055 hasConcept C542903549 @default.
- W4320165055 hasConcept C71924100 @default.
- W4320165055 hasConcept C99454951 @default.
- W4320165055 hasConceptScore W4320165055C126322002 @default.
- W4320165055 hasConceptScore W4320165055C142724271 @default.
- W4320165055 hasConceptScore W4320165055C159654299 @default.
- W4320165055 hasConceptScore W4320165055C177713679 @default.
- W4320165055 hasConceptScore W4320165055C203014093 @default.
- W4320165055 hasConceptScore W4320165055C204787440 @default.
- W4320165055 hasConceptScore W4320165055C27081682 @default.
- W4320165055 hasConceptScore W4320165055C2776042228 @default.
- W4320165055 hasConceptScore W4320165055C2777037409 @default.
- W4320165055 hasConceptScore W4320165055C2777832160 @default.
- W4320165055 hasConceptScore W4320165055C2779185760 @default.
- W4320165055 hasConceptScore W4320165055C2779824493 @default.
- W4320165055 hasConceptScore W4320165055C2908647359 @default.
- W4320165055 hasConceptScore W4320165055C542903549 @default.
- W4320165055 hasConceptScore W4320165055C71924100 @default.
- W4320165055 hasConceptScore W4320165055C99454951 @default.
- W4320165055 hasLocation W43201650551 @default.
- W4320165055 hasOpenAccess W4320165055 @default.
- W4320165055 hasPrimaryLocation W43201650551 @default.
- W4320165055 hasRelatedWork W2415118119 @default.
- W4320165055 hasRelatedWork W2752626458 @default.
- W4320165055 hasRelatedWork W2765176827 @default.
- W4320165055 hasRelatedWork W2982894420 @default.
- W4320165055 hasRelatedWork W2999952146 @default.
- W4320165055 hasRelatedWork W3199319179 @default.
- W4320165055 hasRelatedWork W3206116234 @default.
- W4320165055 hasRelatedWork W4205438099 @default.
- W4320165055 hasRelatedWork W4226207128 @default.
- W4320165055 hasRelatedWork W4292737569 @default.
- W4320165055 isParatext "false" @default.
- W4320165055 isRetracted "false" @default.
- W4320165055 workType "article" @default.